Human T-lymphotropic virus and transfusion safety: does one size fit all?
Human T‐cell leukemia viruses (HTLV‐1 and HTLV‐2) are associated with a variety of human diseases, including some severe ones. Transfusion transmission of HTLV through cellular blood components is undeniable. HTLV screening of blood donations became mandatory in different countries to improve the sa...
Gespeichert in:
| Veröffentlicht in: | Transfusion (Philadelphia, Pa.) Pa.), 2016-01, Vol.56 (1), p.249-260 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 260 |
|---|---|
| container_issue | 1 |
| container_start_page | 249 |
| container_title | Transfusion (Philadelphia, Pa.) |
| container_volume | 56 |
| creator | Marano, Giuseppe Vaglio, Stefania Pupella, Simonetta Facco, Giuseppina Catalano, Liviana Piccinini, Vanessa Liumbruno, Giancarlo Maria Grazzini, Giuliano |
| description | Human T‐cell leukemia viruses (HTLV‐1 and HTLV‐2) are associated with a variety of human diseases, including some severe ones. Transfusion transmission of HTLV through cellular blood components is undeniable. HTLV screening of blood donations became mandatory in different countries to improve the safety of blood supplies. In Japan and Europe, most HTLV‐infected donors are HTLV‐1 positive, whereas in the United States a higher prevalence of HTLV‐2 is reported. Many industrialized countries have also introduced universal leukoreduction of blood components, and pathogen inactivation technologies might be another effective preventive strategy, especially if and when generalized to all blood cellular products. Considering all measures available to minimize HTLV blood transmission, the question is what would be the most suitable and cost‐effective strategy to ensure a high level of blood safety regarding these viruses, considering that there is no solution that can be deemed optimal for all countries. |
| doi_str_mv | 10.1111/trf.13329 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760903946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3919009031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4969-953b1345f327f0c9cab0b804c0fb79962c9ce487502ab1f353e4c95777fbee8d3</originalsourceid><addsrcrecordid>eNp10M1KxDAUBeAgio4_C19AAm50Ub1pmqRxIzI4KorKMOIypJ0Eo20zJq06Pr3VUReC2VwI3z1cDkLbBA5I_w7bYA8IpalcQgPCqEhSKdkyGgBkJCGEpmtoPcZHAEglkFW0lnKa5xRggC7Ou1o3eJJU83r24NvgZ67ELy50Eetmitugm2i76HyDo7amnR_hqTcR-8bg6N4Ntq7FuqqON9GK1VU0W99zA92NTifD8-Tq5uxieHKVlJnkMpGMFoRmzNJUWChlqQsocshKsIWQkqf9l8lywSDVBbGUUZOVkgkhbGFMPqUbaG-ROwv-uTOxVbWLpakq3RjfRUUEBwlUZrynu3_oo-9C01_XK8Ykh1x-qv2FKoOPMRirZsHVOswVAfXZr-r7VV_99nbnO7ErajP9lT-F9uBwAV5dZeb_J6nJePQTmSw2XGzN2--GDk-KCyqYur8-U2M-HLPb8aXi9AMPDZIe</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1755960896</pqid></control><display><type>article</type><title>Human T-lymphotropic virus and transfusion safety: does one size fit all?</title><source>MEDLINE</source><source>Wiley Blackwell Single Titles</source><creator>Marano, Giuseppe ; Vaglio, Stefania ; Pupella, Simonetta ; Facco, Giuseppina ; Catalano, Liviana ; Piccinini, Vanessa ; Liumbruno, Giancarlo Maria ; Grazzini, Giuliano</creator><creatorcontrib>Marano, Giuseppe ; Vaglio, Stefania ; Pupella, Simonetta ; Facco, Giuseppina ; Catalano, Liviana ; Piccinini, Vanessa ; Liumbruno, Giancarlo Maria ; Grazzini, Giuliano</creatorcontrib><description>Human T‐cell leukemia viruses (HTLV‐1 and HTLV‐2) are associated with a variety of human diseases, including some severe ones. Transfusion transmission of HTLV through cellular blood components is undeniable. HTLV screening of blood donations became mandatory in different countries to improve the safety of blood supplies. In Japan and Europe, most HTLV‐infected donors are HTLV‐1 positive, whereas in the United States a higher prevalence of HTLV‐2 is reported. Many industrialized countries have also introduced universal leukoreduction of blood components, and pathogen inactivation technologies might be another effective preventive strategy, especially if and when generalized to all blood cellular products. Considering all measures available to minimize HTLV blood transmission, the question is what would be the most suitable and cost‐effective strategy to ensure a high level of blood safety regarding these viruses, considering that there is no solution that can be deemed optimal for all countries.</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1111/trf.13329</identifier><identifier>PMID: 26388300</identifier><identifier>CODEN: TRANAT</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Blood & organ donations ; Blood Donors ; Blood Safety - economics ; Blood Safety - methods ; Cost-Benefit Analysis ; Europe - epidemiology ; Global Health ; HTLV-I Infections - diagnosis ; HTLV-I Infections - epidemiology ; HTLV-I Infections - prevention & control ; HTLV-I Infections - transmission ; HTLV-II Infections - diagnosis ; HTLV-II Infections - epidemiology ; HTLV-II Infections - prevention & control ; HTLV-II Infections - transmission ; Human T-lymphotropic virus 1 - isolation & purification ; Human T-lymphotropic virus 2 - isolation & purification ; Humans ; Prevalence ; United States - epidemiology</subject><ispartof>Transfusion (Philadelphia, Pa.), 2016-01, Vol.56 (1), p.249-260</ispartof><rights>2015 AABB</rights><rights>2015 AABB.</rights><rights>2016 AABB</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4969-953b1345f327f0c9cab0b804c0fb79962c9ce487502ab1f353e4c95777fbee8d3</citedby><cites>FETCH-LOGICAL-c4969-953b1345f327f0c9cab0b804c0fb79962c9ce487502ab1f353e4c95777fbee8d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ftrf.13329$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ftrf.13329$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26388300$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marano, Giuseppe</creatorcontrib><creatorcontrib>Vaglio, Stefania</creatorcontrib><creatorcontrib>Pupella, Simonetta</creatorcontrib><creatorcontrib>Facco, Giuseppina</creatorcontrib><creatorcontrib>Catalano, Liviana</creatorcontrib><creatorcontrib>Piccinini, Vanessa</creatorcontrib><creatorcontrib>Liumbruno, Giancarlo Maria</creatorcontrib><creatorcontrib>Grazzini, Giuliano</creatorcontrib><title>Human T-lymphotropic virus and transfusion safety: does one size fit all?</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>Human T‐cell leukemia viruses (HTLV‐1 and HTLV‐2) are associated with a variety of human diseases, including some severe ones. Transfusion transmission of HTLV through cellular blood components is undeniable. HTLV screening of blood donations became mandatory in different countries to improve the safety of blood supplies. In Japan and Europe, most HTLV‐infected donors are HTLV‐1 positive, whereas in the United States a higher prevalence of HTLV‐2 is reported. Many industrialized countries have also introduced universal leukoreduction of blood components, and pathogen inactivation technologies might be another effective preventive strategy, especially if and when generalized to all blood cellular products. Considering all measures available to minimize HTLV blood transmission, the question is what would be the most suitable and cost‐effective strategy to ensure a high level of blood safety regarding these viruses, considering that there is no solution that can be deemed optimal for all countries.</description><subject>Blood & organ donations</subject><subject>Blood Donors</subject><subject>Blood Safety - economics</subject><subject>Blood Safety - methods</subject><subject>Cost-Benefit Analysis</subject><subject>Europe - epidemiology</subject><subject>Global Health</subject><subject>HTLV-I Infections - diagnosis</subject><subject>HTLV-I Infections - epidemiology</subject><subject>HTLV-I Infections - prevention & control</subject><subject>HTLV-I Infections - transmission</subject><subject>HTLV-II Infections - diagnosis</subject><subject>HTLV-II Infections - epidemiology</subject><subject>HTLV-II Infections - prevention & control</subject><subject>HTLV-II Infections - transmission</subject><subject>Human T-lymphotropic virus 1 - isolation & purification</subject><subject>Human T-lymphotropic virus 2 - isolation & purification</subject><subject>Humans</subject><subject>Prevalence</subject><subject>United States - epidemiology</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10M1KxDAUBeAgio4_C19AAm50Ub1pmqRxIzI4KorKMOIypJ0Eo20zJq06Pr3VUReC2VwI3z1cDkLbBA5I_w7bYA8IpalcQgPCqEhSKdkyGgBkJCGEpmtoPcZHAEglkFW0lnKa5xRggC7Ou1o3eJJU83r24NvgZ67ELy50Eetmitugm2i76HyDo7amnR_hqTcR-8bg6N4Ntq7FuqqON9GK1VU0W99zA92NTifD8-Tq5uxieHKVlJnkMpGMFoRmzNJUWChlqQsocshKsIWQkqf9l8lywSDVBbGUUZOVkgkhbGFMPqUbaG-ROwv-uTOxVbWLpakq3RjfRUUEBwlUZrynu3_oo-9C01_XK8Ykh1x-qv2FKoOPMRirZsHVOswVAfXZr-r7VV_99nbnO7ErajP9lT-F9uBwAV5dZeb_J6nJePQTmSw2XGzN2--GDk-KCyqYur8-U2M-HLPb8aXi9AMPDZIe</recordid><startdate>201601</startdate><enddate>201601</enddate><creator>Marano, Giuseppe</creator><creator>Vaglio, Stefania</creator><creator>Pupella, Simonetta</creator><creator>Facco, Giuseppina</creator><creator>Catalano, Liviana</creator><creator>Piccinini, Vanessa</creator><creator>Liumbruno, Giancarlo Maria</creator><creator>Grazzini, Giuliano</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201601</creationdate><title>Human T-lymphotropic virus and transfusion safety: does one size fit all?</title><author>Marano, Giuseppe ; Vaglio, Stefania ; Pupella, Simonetta ; Facco, Giuseppina ; Catalano, Liviana ; Piccinini, Vanessa ; Liumbruno, Giancarlo Maria ; Grazzini, Giuliano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4969-953b1345f327f0c9cab0b804c0fb79962c9ce487502ab1f353e4c95777fbee8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Blood & organ donations</topic><topic>Blood Donors</topic><topic>Blood Safety - economics</topic><topic>Blood Safety - methods</topic><topic>Cost-Benefit Analysis</topic><topic>Europe - epidemiology</topic><topic>Global Health</topic><topic>HTLV-I Infections - diagnosis</topic><topic>HTLV-I Infections - epidemiology</topic><topic>HTLV-I Infections - prevention & control</topic><topic>HTLV-I Infections - transmission</topic><topic>HTLV-II Infections - diagnosis</topic><topic>HTLV-II Infections - epidemiology</topic><topic>HTLV-II Infections - prevention & control</topic><topic>HTLV-II Infections - transmission</topic><topic>Human T-lymphotropic virus 1 - isolation & purification</topic><topic>Human T-lymphotropic virus 2 - isolation & purification</topic><topic>Humans</topic><topic>Prevalence</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marano, Giuseppe</creatorcontrib><creatorcontrib>Vaglio, Stefania</creatorcontrib><creatorcontrib>Pupella, Simonetta</creatorcontrib><creatorcontrib>Facco, Giuseppina</creatorcontrib><creatorcontrib>Catalano, Liviana</creatorcontrib><creatorcontrib>Piccinini, Vanessa</creatorcontrib><creatorcontrib>Liumbruno, Giancarlo Maria</creatorcontrib><creatorcontrib>Grazzini, Giuliano</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marano, Giuseppe</au><au>Vaglio, Stefania</au><au>Pupella, Simonetta</au><au>Facco, Giuseppina</au><au>Catalano, Liviana</au><au>Piccinini, Vanessa</au><au>Liumbruno, Giancarlo Maria</au><au>Grazzini, Giuliano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human T-lymphotropic virus and transfusion safety: does one size fit all?</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2016-01</date><risdate>2016</risdate><volume>56</volume><issue>1</issue><spage>249</spage><epage>260</epage><pages>249-260</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><coden>TRANAT</coden><abstract>Human T‐cell leukemia viruses (HTLV‐1 and HTLV‐2) are associated with a variety of human diseases, including some severe ones. Transfusion transmission of HTLV through cellular blood components is undeniable. HTLV screening of blood donations became mandatory in different countries to improve the safety of blood supplies. In Japan and Europe, most HTLV‐infected donors are HTLV‐1 positive, whereas in the United States a higher prevalence of HTLV‐2 is reported. Many industrialized countries have also introduced universal leukoreduction of blood components, and pathogen inactivation technologies might be another effective preventive strategy, especially if and when generalized to all blood cellular products. Considering all measures available to minimize HTLV blood transmission, the question is what would be the most suitable and cost‐effective strategy to ensure a high level of blood safety regarding these viruses, considering that there is no solution that can be deemed optimal for all countries.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>26388300</pmid><doi>10.1111/trf.13329</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1132 |
| ispartof | Transfusion (Philadelphia, Pa.), 2016-01, Vol.56 (1), p.249-260 |
| issn | 0041-1132 1537-2995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1760903946 |
| source | MEDLINE; Wiley Blackwell Single Titles |
| subjects | Blood & organ donations Blood Donors Blood Safety - economics Blood Safety - methods Cost-Benefit Analysis Europe - epidemiology Global Health HTLV-I Infections - diagnosis HTLV-I Infections - epidemiology HTLV-I Infections - prevention & control HTLV-I Infections - transmission HTLV-II Infections - diagnosis HTLV-II Infections - epidemiology HTLV-II Infections - prevention & control HTLV-II Infections - transmission Human T-lymphotropic virus 1 - isolation & purification Human T-lymphotropic virus 2 - isolation & purification Humans Prevalence United States - epidemiology |
| title | Human T-lymphotropic virus and transfusion safety: does one size fit all? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T17%3A09%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20T-lymphotropic%20virus%20and%20transfusion%20safety:%20does%20one%20size%20fit%20all?&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=Marano,%20Giuseppe&rft.date=2016-01&rft.volume=56&rft.issue=1&rft.spage=249&rft.epage=260&rft.pages=249-260&rft.issn=0041-1132&rft.eissn=1537-2995&rft.coden=TRANAT&rft_id=info:doi/10.1111/trf.13329&rft_dat=%3Cproquest_cross%3E3919009031%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1755960896&rft_id=info:pmid/26388300&rfr_iscdi=true |